Rajeev Saggar

CMO Rajeev Saggar sells 9,926 shares ($709.8K) at $71.51 avg under 10b5-1 plan; retains 171.8K shares plus 66,046 derivative holdings

Rajeev Saggar, Chief Medical Officer of Liquidia Corp, executed 2 separate sales totaling 9,926 shares for $709,816.13 on 2026-07-13 under a pre-arranged 10b5-1 trading plan adopted on 2023-12-15. His post-transaction non-derivative holdings remain at 171,799 shares, with an additional 66,046 shares held in derivative form (Performance Stock Units). The stock traded at $76.49 at filing time, representing a 52-week position of -7.8% from the $82.96 high. Over the same quarterly period, the stock has advanced +7.4% (30-day) and +90.6% (90-day). Liquidia's fundamentals show a dramatic revenue expansion (+1031.2% annual growth) with $52.9M net income in the latest quarter, though full-year results were negative; the P/E of 305.96 reflects a highly compressed earnings multiple. The scheduled nature of this transaction precludes timing-based analysis, and the insider's substantial derivative stake and retained common holdings indicate material ongoing economic exposure to the company.

Chief Medical Officer Rajeev Saggar sold 35,365 shares of Liquidia (LQDA) at $36.30 for $1.3M, reducing stake by 16.9% to 174,473 shares.

Saggar sold approximately 16.9% of his LQDA holdings—a substantial reduction from 209,838 to 174,473 shares—on 2026-03-13, when the stock was trading at $36.30 and currently sits at $36.86, roughly -21.0% below its 52-week high of $46.63. At the same ticker, prior trades by Saggar have shown mixed outcomes: his January 2026 sale was up 7.3% in 30 days, his November sales posted strong 72.7% gains over 90 days, but his August 2025 sale saw a -21.7% 30-day decline despite a +13.9% 90-day recovery. The company remains unprofitable (net income $-3.5M) despite extraordinary revenue growth of 1031.2% year-over-year, raising questions about margin trajectory and cash burn. This large, discretionary sale by the Chief Medical Officer warrants review of the context—whether it reflects portfolio reallocation, personal liquidity needs, or any underlying operational signals.

CMO Rajeev Saggar sold 21,142 shares of LQDA at $37.43 on 2026-01-12 for $791,345.06 while stock near 52-week high.

Saggar sold 21.1K shares at $37.43, reducing holdings by 10.7% to 176.9K shares while the stock was near its 52-week peak of $38.09. The sale occurred after a strong 30-day gain of +14.1% and a 90-day surge of +64.5%, suggesting execution near elevated levels. However, his prior trade outcomes at LQDA provide limited signal: two recent November 2025 sells each showed +27.4% 30-day returns (outcome not yet measurable at 90 days), while a 2025-08-28 sale proved poorly timed with a +13.9% 90-day gain after the transaction. Against a backdrop of -20.0% annual revenue growth and an unprofitable company with -$3.5M net income in the latest quarter, the sale's timing relative to fundamental weakness remains ambiguous without contemporaneous information on CMO motivations.

CMO Rajeev Saggar sells 71,381 shares (28.8% of holdings) at $27.00 for $1.9M at Liquidia (LQDA)

Rajeev Saggar, Chief Medical Officer at Liquidia, executed 2 separate sales totaling 71,381 shares for $1,927,287.00 at a blended average price of $27.00, reducing his holdings by 28.8%. The company faces headwinds: it reported annual revenue growth of -20.0%, generated a net loss of $-3,533,000.00 on quarterly revenue of $54,342,000.00, and remains unprofitable. Saggar's prior cross-ticker trading history shows only 1 prior sell with an average 30-day return of -21.7%; however, his prior trade at LQDA (a sell on 2025-08-28) also showed 30-day returns of -21.7%, making current timing assessment limited. The stock currently trades at $26.09, down 10.7% from its 52-week high of $29.22 but up 8.4% over 30 days and up 27.6% over 90 days, suggesting the sales occurred near recent price peaks.

CMO Rajeev Saggar sells 20,000 LQDA shares at $27.85; stock at 52-week high while company unprofitable with -20.0% revenue decline

Rajeev Saggar, Chief Medical Officer, sold 20,000 shares (7.4% of pre-transaction holdings) at $27.85 on 2025-08-28, leaving holdings of 249,727 shares. The transaction occurred when LQDA's stock price was at its 52-week high of $28.58 (current price shows the stock reached exactly this high). This sale coincides with a sharp 30-day gain of +61.6% and a 90-day gain of +62.4%, suggesting the stock recently rallied substantially. However, Liquidia's fundamentals show deterioration: annual revenue declined -20.0% to $8.8M in the latest quarter, and the company posted a full-year net loss of $-41.6M. The insider's sale into a 52-week high after a multi-month rally, combined with deteriorating profitability metrics and negative revenue growth, presents a divergence between price momentum and operational trends that warrants investor scrutiny of the company's near-term outlook.